MacroGenics, Inc. (NASDAQ:MGNX) shares increased 1.46% in last trading session and ended the day at $31.91. And its has a return on assets of -3.90%. MacroGenics, Inc. (NASDAQ:MGNX) quarterly performance is -0.65%.
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, announced that interim results of an ongoing Phase 1 dose-escalation study of enoblituzumab (MGA271) were presented in the late-breaking abstract session today at the 2015 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD. Dr. John Powderly II of the Carolina BioOncology Institute, Huntersville, NC, presented “Interim Results of an Ongoing Phase 1, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3.
Gulf Resources, Inc. (NASDAQ:GURE) ended the last trading day at $1.83. Company weekly volatility is calculated as 6.08% and price to cash ratio as 0.72. Gulf Resources, Inc. (NASDAQ:GURE) showed a weekly performance of -1.08%.
Gulf Resources (NASDAQ:GURE) announced its quarterly earnings data on Tuesday. The company reported $0.23 earnings per share for the quarter. The company had revenue of $42.60 million for the quarter, compared to analyst estimates of $31.10 million.
On 13 November, ExamWorks Group, Inc. (NYSE:EXAM) shares decreased -0.41% and was closed at $24.05. EXAM EPS growth in last 5 year was 21.00%. ExamWorks Group, Inc. (NYSE:EXAM) year to date (YTD) performance is -42.17%.
ExamWorks Group, Inc. (NYSE: EXAM), reported financial results for the third quarter of 2015. Financial Review Revenues – For the three months ended September 30, 2015, revenues were $206.0 million, an increase of 1.0% over the $204.1 million of revenues generated in the third quarter of 2014.For the nine months ended September 30, 2015, revenues were $611.1 million, an increase of 6.5% over the $573.6 million of revenues generated in the comparable period in 2014.
Opexa Therapeutics, Inc. (NASDAQ:OPXA) shares decreased -1.49% in last trading session and ended the day at $3.30. And its has a return on assets of -97.40%. Opexa Therapeutics, Inc. (NASDAQ:OPXA) quarterly performance is 8.55%.
Opexa Therapeutics, Inc. (NASDAQ: OPXA), reported financial results for the three months ended September 30, 2015 and provided an update on the Company’s recent corporate developments. Opexa reported revenue of $726,291 and $307,686 for the three months ended September 30, 2015 and 2014, respectively. The revenue is related to the recognized portion of the $5 million upfront payment received from Merck Serono in conjunction with the Option and License Agreement entered into between Opexa and Merck Serono during February 2013 and the $3 million payment from Merck Serono in connection with the March 2015 amendment. In September 2015, Opexa entered into a stock purchase agreement with investors to fund the Company’s NMO program, including its planned Phase 1/2 trial, pursuant to which Opexa sold in tranche one of a private placement 113,636 shares of common stock for a per share purchase price of $4.40 and issued warrants to purchase a like number of shares, for a total purchase price of $499,999.
Teekay Offshore Partners LP (NYSE:TOO) caters to the Services space. It has a net profit margin of 6.00% and weekly performance is -9.66%. On the last day of trading company shares ended up at $13.00. Teekay Offshore Partners LP (NYSE:TOO) distance from 50-day simple moving average (SMA50) is -16.39%.
Teekay Offshore GP LLC, the general partner of Teekay Offshore Partners LP (NYSE:TOO) reported the Partnership’s results for the quarter ended September 30, 2015. During the third quarter of 2015, the Partnership generated distributable cash flow(1) of $58.8 million, compared to $45.2 million in the same period of the prior year. The increase in distributable cash flow was primarily due to the acquisition of the Petrojarl Knarr (Knarr) floating production, storage and offloading (FPSO) unit in July 2015, the acquisition of six long-distance towing and offshore installation vessels during the first seven months of 2015, and the commencement of the Arendal Spirit Unit for Maintenance and Safety (UMS) charter contract in early-June 2015. These increases were partially offset by the expiration of two shuttle tanker contracts in the second quarter of 2015, as well as the temporary shut-down on the Piranema Spirit FPSO unit for unscheduled repairs, which were completed during the third quarter of 2015.
Leave a Reply